Oxyntomodulin analogs
US9593155B2 · kind B2 · utility
1Cited by
3References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 14, 2015 |
| Grant date | Mar 14, 2017 |
| Priority date | — |
| Expiry date | Apr 14, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonist are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.